Physician profile
William H Moore
NPI 1891791547
$1,012.80
in general payments reported to CMS, 2019-2025
16 companies · $258 in 2025
The $258 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $113 · 2021: $146 · 2022: $95.21 · 2023: $125 · 2024: $153 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $183.54 | 2019-2025 | Doc Band |
| Pfizer INC. | $164.46 | 2022-2025 | |
| Tris Pharma INC | $118.25 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $110.91 | 2023-2025 | Azstarys |
| Adlon Therapeutics L.P. | $97.60 | 2020-2021 | |
| Sanofi Pasteur INC. | $93.10 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $50.36 | 2021-2024 | M-M-R II, Vaxneuvance, Gardasil 9 |
| Seqirus USA INC | $33.20 | 2021-2023 | Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $27.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $25.43 | 2024 | Bexsero, Rotarix, Pediarix |
| Genentech USA, INC. | $20.82 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.06 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.00 | 2019 | |
| Shire North American Group INC | $14.55 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.